- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 580135, 8 pages
TNFα Mediated IL-6 Secretion Is Regulated by JAK/STAT Pathway but Not by MEK Phosphorylation and AKT Phosphorylation in U266 Multiple Myeloma Cells
1Cancer Research Institute, College of Medicine, Seoul National University, 101 Daehak-ro, Jongro-gu, Seoul 110-799, Republic of Korea
2Clinical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongro-gu, Seoul 110-799, Republic of Korea
3Hematology and Medical Oncology, Dongguk University Ilsan Hospital, 27 Dongguk-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-773, Republic of Korea
4Department of Laboratory Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongro-gu, Seoul 110-799, Republic of Korea
5Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongro-gu, Seoul 110-799, Republic of Korea
Received 7 June 2013; Revised 15 August 2013; Accepted 16 August 2013
Academic Editor: Susanne Saussele
Copyright © 2013 Chansu Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- T. Hideshima and K. C. Anderson, “Molecular mechanisms of novel therapeutic approaches for multiple myeloma,” Nature Reviews Cancer, vol. 2, no. 12, pp. 927–937, 2002.
- S. Singhal and J. Mehta, “Novel therapies in multiple myeloma,” International Journal of Hematology, vol. 77, no. 3, pp. 226–231, 2003.
- T. Hideshima, D. Chauhan, K. Podar, R. L. Schlossman, P. Richardson, and K. C. Anderson, “Novel therapies targeting the myeloma cell and its bone marrow microenvironment,” Seminars in Oncology, vol. 28, no. 6, pp. 607–612, 2001.
- M. B. Meads, L. A. Hazlehurst, and W. S. Dalton, “The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance,” Clinical Cancer Research, vol. 14, no. 9, pp. 2519–2526, 2008.
- Y. Nefedova, T. H. Landowski, and W. S. Dalton, “Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms,” Leukemia, vol. 17, no. 6, pp. 1175–1182, 2003.
- K. Podar, P. G. Richardson, T. Hideshima, D. Chauhan, and K. C. Anderson, “The malignant clone and the bone-marrow environment,” Best Practice and Research in Clinical Haematology, vol. 20, no. 4, pp. 597–612, 2007.
- C. S. Mitsiades, D. W. McMillin, S. Klippel et al., “The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies,” Hematology/Oncology Clinics of North America, vol. 21, no. 6, pp. 1007–1034, 2007.
- M. G. Alexandrakis, F. H. Passam, A. Sfiridaki, E. Kandidaki, P. Roussou, and D. S. Kyriakou, “Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity,” The American Journal of Hematology, vol. 72, no. 4, pp. 229–233, 2003.
- Y. Cao, T. Luetkens, S. Kobold et al., “The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients,” Experimental Hematology, vol. 38, no. 10, pp. 860–867, 2010.
- R. Aggarwal, I. M. Ghobrial, and G. D. Roodman, “Chemokines in multiple myeloma,” Experimental Hematology, vol. 34, no. 10, pp. 1289–1295, 2006.
- L. M. Coe, R. Irwin, D. Lippner, and L. R. McCabe, “The bone marrow microenvironment contributes to type I diabetes induced osteoblast death,” Journal of Cellular Physiology, vol. 226, no. 2, pp. 477–483, 2011.
- X. Lu, G. R. Beck Jr., L. C. Gilbert et al., “Identification of the homeobox protein Prx1 (MHox, Prrx-1) as a regulator of osterix expression and mediator of tumor necrosis factor α action in osteoblast differentiation,” Journal of Bone and Mineral Research, vol. 26, no. 1, pp. 209–219, 2011.
- K. Bommert, R. C. Bargou, and T. Stühmer, “Signalling and survival pathways in multiple myeloma,” European Journal of Cancer, vol. 42, no. 11, pp. 1574–1580, 2006.
- M. M. Kawano, H. Ishikawa, N. Tsuyama et al., “Growth mechanism of human myeloma cells by interleukin-6,” International Journal of Hematology, vol. 76, supplement 1, pp. 329–333, 2002.
- R. D. Devlin, S. V. Reddy, R. Savino, G. Ciliberto, and G. D. Roodman, “IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures,” Journal of Bone and Mineral Research, vol. 13, no. 3, pp. 393–399, 1998.
- V. Baud and M. Karin, “Is NF-κB a good target for cancer therapy? Hopes and pitfalls,” Nature Reviews Drug Discovery, vol. 8, no. 1, pp. 33–40, 2009.
- B. Zdzisińska, A. Bojarska-Junak, A. Dmoszyńska, and M. Kandefer-Szerszeń, “Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells,” Archivum Immunologiae et Therapiae Experimentalis, vol. 56, no. 3, pp. 207–221, 2008.
- R. H. Prabhala, D. Pelluru, M. Fulciniti et al., “Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma,” Blood, vol. 115, no. 26, pp. 5385–5392, 2010.
- H. Wajant, K. Pfizenmaier, and P. Scheurich, “Tumor necrosis factor signaling,” Cell Death and Differentiation, vol. 10, no. 1, pp. 45–65, 2003.
- G. Chen and D. V. Goeddel, “TNF-R1 signaling: a beautiful pathway,” Science, vol. 296, no. 5573, pp. 1634–1635, 2002.
- M. A. Thompson, T. E. Witzig, S. Kumar et al., “Plasma levels of tumour necrosis factor α and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma,” The British Journal of Haematology, vol. 123, no. 2, pp. 305–308, 2003.
- H. I. A. Sati, M. Greaves, J. F. Apperley, R. G. G. Russell, and P. I. Croucher, “Expression of interleukin-1β and tumour necrosis factor-α in plasma cells from patients with multiple myeloma,” The British Journal of Haematology, vol. 104, no. 2, pp. 350–357, 1999.
- A. Lichtenstein, J. Berenson, D. Norman, M. P. Chang, and A. Carlile, “Production of cytokines by bone marrow cells obtained from patients with multiple myeloma,” Blood, vol. 74, no. 4, pp. 1266–1273, 1989.
- S. Markovina, N. S. Callander, S. L. O'Connor et al., “Bortezomib-resistant nuclear factor-κB activity in multiple myeloma cells,” Molecular Cancer Research, vol. 6, no. 8, pp. 1356–1364, 2008.
- D. Chauhan, H. Uchiyama, Y. Akbarali et al., “Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB,” Blood, vol. 87, no. 3, pp. 1104–1112, 1996.
- T. Sanda, S. Iida, H. Ogura et al., “Growth inhibition of multiple myeloma cells by a novel IκB kinase inhibitor,” Clinical Cancer Research, vol. 11, no. 5, pp. 1974–1982, 2005.
- Y. Dai, X. Y. Pei, M. Rahmani, D. H. Conrad, P. Dent, and S. Grant, “Interruption of the NF-κB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells,” Blood, vol. 103, no. 7, pp. 2761–2770, 2004.
- T. Hideshima, P. Neri, P. Tassone et al., “MLN120B, a novel IκB kinase β inhibitor, blocks multiple myeloma cell growth in vitro and in vivo,” Clinical Cancer Research, vol. 12, no. 19, pp. 5887–5894, 2006.
- K. H. Ha, M. S. Byun, J. Choi, J. Jeong, K. J. Lee, and D. M. Jue, “N-tosyl-L-phenylalanine chloromethyl ketone inhibits NF-κB activation by blocking specific cysteine residues of IκB kinase β and p65/RelA,” Biochemistry, vol. 48, no. 30, pp. 7271–7278, 2009.
- W. Wang, J. L. Abbruzzese, D. B. Evans, and P. J. Chiao, “Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA,” Oncogene, vol. 18, no. 32, pp. 4554–4563, 1999.
- O. W. Rokhlin, N. V. Guseva, A. F. Taghiyev, R. A. Glover, and M. B. Cohen, “Multiple effects of N-α-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines,” Cancer Biology and Therapy, vol. 3, no. 8, pp. 761–768, 2004.